Spreading depolarization-modulating drugs and delayed cerebral ischemia after subarachnoid hemorrhage: A hypothesis-generating retrospective clinical study

Publication date

2016-07-15

Authors

Hamming, Arend M
Mulder, Inge A.
Gathier, Celine SISNI 0000000393005873
van den Bergh, Walter M.ISNI 000000039182746X
Dankbaar, Jan WISNI 0000000392895296
Hoff, Reinier GISNI 0000000387268941
Vandertop, W. Peter
Verbaan, Dagmar
Ferrari, Michel D.
Rinkel, Gabriel J EISNI 0000000388847590

Editors

Advisors

Supervisors

Document Type

Article

Collections

License

Abstract

Background Delayed cerebral ischemia (DCI) occurs in approximately one-third of patients with aneurysmal subarachnoid hemorrhage (aSAH). A proposed underlying mechanism for DCI is spreading depolarization (SD). Our aim was to, retrospectively, investigate the influence of the use of SD-modulating drugs on the occurrence of DCI. Methods We, retrospectively, combined data from four cohorts of aSAH patients with data on the use of home medication prior to hospital admission, occurrence of DCI, and clinical outcome. Home medication was classified as "SD-inhibiting", "SD-facilitating", or "SD-neutral based" on a comprehensive literature review. We defined subgroups "likely", "possibly" and "weak" concerning the amount of evidence in literature. We performed Cox and Poisson regression analysis and calculated hazard ratios (HR) and risk ratios (RR) for the influence of "SD-modulating" drugs on primary outcome measure DCI and secondary outcome measure poor clinical outcome (modified Rankin Scale ≥ 3) three months after aSAH. We adjusted for age, sex and clinical condition on admission (aHR/aRR). Results DCI occurred in 343 (29%) of 1194 patients. Patients using SD-inhibiting home medication had an aHR for DCI of 0.66 (95% CI: 0.42-1.06) and an aRR for poor outcome of 1.13 (95% CI: 0.90-1.41). Patients using SD-facilitating drugs had an aHR for DCI of 1.24 (95% CI: 0.83-1.87) and an aRR for poor outcome of 1.19 (95% CI: 0.95-1.50). When comparing patients using SD-inhibiting drugs with patients using SD-facilitating drugs, the aHR was 0.54 (95% CI: 0.29-0.99) for DCI and the aRR 0.97 (95% CI: 0.71-1.32) for outcome. Conclusions In this exploratory study chronic use of SD-inhibiting drugs tended to reduce DCI but did not result in a better clinical outcome. Additional research is needed to investigate the specific effects of SD-modulation on DCI and outcome and to further explore its effectiveness in preventing DCI after aSAH.

Keywords

Cortical spreading depression, Delayed cerebral ischemia, Drugs, Secondary ischemia, Spreading depolarizations, Subarachnoid hemorrhage, Clinical Neurology, Neurology, Journal Article, Clinical Study

Citation

Hamming, A M, Mulder, I A, Gathier, C S, Van Den Bergh, W M, Dankbaar, J W, Hoff, R G, Vandertop, W P, Verbaan, D, Ferrari, M D, Rinkel, G J E, Algra, A & Wermer, M J H 2016, 'Spreading depolarization-modulating drugs and delayed cerebral ischemia after subarachnoid hemorrhage : A hypothesis-generating retrospective clinical study', Journal of the Neurological Sciences, vol. 366, pp. 224-228. https://doi.org/10.1016/j.jns.2016.04.056